HOME >> BIOLOGY >> NEWS
LA BioMed Medical/Research Briefs, July/August 2004

  • LA BioMed Supports Stem Cell Initiative
  • Ethnic Breast Cancer?
  • A Periodic Table For Biology

    La BioMed Supports Stem Cell Initiative

    In coalition with major health and business groups throughout California, LA BioMed has indicated its support for the California Stem Cell Bond Issue Initiative that recently qualified for November's ballot. The initiative will allocate money from a $3 billion bond to fund promising, California-based stem cell research.

    The initiative will distribute an average of $295 million per year over a 10-year period to fund stem cell research at California's universities and other advanced medical research facilities. It will fund all aspects of stem cell therapy development from basic research through clinical trials to the actual delivery of therapies to patients.

    Kenneth P. Trevett, President and CEO of LA BioMed, recently issued the following statement about the initiative:

    The stem cell initiative is a necessary step in the pursuit of scientific research because federal funding for stem cell research has been limited. Unquestionably, stem cell therapy is potentially the most important medical advance since the discovery of antibiotics. This critically important statewide initiative closes the federal funding gap and sets a new state model for advancing scientific research. From an economic standpoint, California will benefit from patents and royalties that result from the research. Construction of research facilities and new research jobs will generate millions of dollars in new tax revenues for California. More importantly, if stem cell research results in a single cure that reduces healthcare costs by just one percent, it would pay for itself several times over during the following decade and save lives along the way.

    Mr. Trevett is available to speak the merits of the stem cell initiative. To contact him, telephone or e-mail the Communicatio
    '"/>



  • Contact: David Feuerherd
    df@issuesmanagement.com
    310-215-0234
    Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
    30-Jul-2004


    Page: 1 2 3

    Related biology news :

    1. BioMed Central to consult funders and librarians over Open Access payment model
    2. BioMed Central explodes Open Access myths
    3. The Scientist and BioMed Central come together to publish high-impact magazine
    4. BioMed Central is pleased to announce the publication of Sydney Brenners autobiography
    5. BioMed Central to deposit e-journals with the British Library
    6. BioMed Central to consider charging authors for paper submissions
    7. Get Research on the move with BioMed Central
    8. BioMed Central to launch at microbiology meeting
    9. BioMed Central to free scientists and clinical researchers from copyright restrictions

    Post Your Comments:
    *Name:
    *Comment:
    *Email:


    (Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
    (Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
    (Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
    Breaking Biology News(10 mins):
    (Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
    (Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
    (Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
    (Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division ... tuned and optimized exclusively for Okuma CNC machining centers at The International Manufacturing ... collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics and ...
    Breaking Biology Technology:
    Cached News: